NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Shares of Madrigal Pharmaceuticals and VistaGen were both on fire in Wednesday trading. Madrigal Pharmaceuticals announced positive data from mid-stage results on its NASH drug, MGL-3196 while VistaGen announced it had been awarded a patent for AV-101, its lead CNS product candidate.

RDI Initiates Coverage on:

Madrigal Pharmaceuticals, Inc.
http://www.rdinvesting.com/report/?ticker=MDGL

VistaGen Therapeutics, Inc.
http://www.rdinvesting.com/report/?ticker=VTGN

Madrigal Pharmaceuticals, Inc. shares closed up 88.29% on Wednesday, making it one of the biggest advancers on the NASDAQ board. The stock also hit a new high of $101 on explosive trading volume compared to usual yesterday. The gains came after the company delivered positive mid-stage results on its experimental non-alcoholic steatohepatitis (NASH) drug, MGL-3196. Patients that had been treated with MGL-3196 experienced a significant decline in the amount of fat in the liver compared to those receiving a placebo. The lead investigator on the study, Dr. Stephen Harrison, M.D. commented, "NASH is a common liver disease in the United States, with a growing prevalence, for which no FDA approved treatment is yet available. These results suggest that a highly selective liver-directed, thyroid hormone receptor-? agonist may be able to effectively and safely treat patients with NASH. Importantly, the study is designed to allow correlations between efficacy in a non-invasive imaging test, MRI-PDFF at 12 and 36 weeks, and improvement in NASH on liver biopsy at 36 weeks."

Access RDI's Madrigal Pharmaceuticals, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=MDGL

VistaGen Therapeutics, Inc. shares exploded on Wednesday and closed the day up 93.55% on over 40 million shares traded. The stock was one of the biggest gainers on the NASDAQ after it was reported that the clinical-stage biopharmaceutical company had been issued a patent by the U.S. Patent and Trademark Office (USPTO). The office has issued U.S. Patent No. 9,834,801 related to certain methods of production for AV-101, which is VistaGen's lead CNS product candidate. CEO Shawn Singh commented, "The issuance of this U.S. patent by the USPTO advances our intellectual property strategy for AV-101 at this vital period in its clinical development. This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential."

Access RDI's VistaGen Therapeutics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=VTGN

Our Actionable Research on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) and VistaGen Therapeutics, Inc. (NASDAQ: VTGN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com